Earnings Surprises
Biggest EPS beats and misses, ranked by post-earnings price reaction. Free data, no paywall.
Ranked by EPS surprise % (highest first). Price reaction = day after report.
| # | Symbol | Company | Sector | Date | EPS Actual | EPS Est. | Surprise | Price Reaction |
|---|---|---|---|---|---|---|---|---|
| 1 | Galapagos N.V. | Healthcare | Feb 23, 2026 | $16.38 | $1.00 | +1538% | +1.8% | |
| 2 | BioCryst Pharmaceuticals, Inc. | Healthcare | Feb 26, 2026 | $1.12 | $0.07 | +1500% | +15.9% | |
| 3 | STAAR Surgical Company | Healthcare | May 13, 2026 | $0.38 | $0.03 | +1262% | +13.6% | |
STAAR is off to a strong start in 2026, as reflected in our first quarter financial results. We have made meaningful advancements against our core objectives of Revenue Growth and Profit Expansion. | ||||||||
| 4 | ACADIA Pharmaceuticals Inc. | Healthcare | Feb 25, 2026 | $1.60 | $0.14 | +1068% | +0.2% | |
| 5 | iRhythm Technologies, Inc. | Healthcare | Feb 19, 2026 | $0.17 | $0.02 | +750% | -1.9% | |
| 6 | CareDx, Inc | Healthcare | Feb 24, 2026 | $0.12 | $0.02 | +503% | -1.8% | |
| 7 | Innoviva, Inc. | Healthcare | Feb 25, 2026 | $1.94 | $0.34 | +471% | +0.5% | |
| 8 | Fortrea Holdings Inc. | Healthcare | May 5, 2026 | $0.16— Maintained | $0.03 | +433% | +27.7% | |
We started the year strong, focused on delivering for our clients with excellence and making advances in our strategic journey back to growth and margin expansion. | ||||||||
| 9 | Alignment Healthcare, Inc. | Healthcare | Apr 30, 2026 | $0.05↑ Raised | $0.01 | +400% | -6.7% | |
John Kao, founder and CEO Our first-quarter performance demonstrates that Alignment continues to grow with discipline. We expanded our profitability by executing across sales, clinical operations and cost management, even as the Medicare Advantage environment continues to change. | ||||||||
| 10 | Arcutis Biotherapeutics, Inc. | Healthcare | Feb 25, 2026 | $0.13 | $0.03 | +333% | +5.9% | |
| 11 | BioLife Solutions, Inc. | Healthcare | May 7, 2026 | $0.04— Maintained | $0.01 | +300% | +1.3% | |
We delivered a solid start to 2026, with first quarter revenue up 25% year-over-year and adjusted EBITDA of $6.2 million. Healthy demand for our biopreservation media and growth across our broader product portfolio reinforces our market leading position. | ||||||||
| 12 | LifeStance Health Group, Inc. | Healthcare | May 7, 2026 | $0.04↑ Raised | $0.01 | +300% | +4.5% | |
We delivered an exceptional quarter to begin the year, highlighted by strong revenue growth of 21%, net income growth of $13.5 million, and Adjusted EBITDA growth of 48%. | ||||||||
| 13 | Astrana Health, Inc. | Healthcare | Mar 2, 2026 | $0.54 | $0.15 | +260% | +20.6% | |
| 14 | Hims & Hers Health, Inc. | Healthcare | Feb 23, 2026 | $0.07 | $0.02 | +250% | -1.1% | |
| 15 | Supernus Pharmaceuticals, Inc. | Healthcare | Feb 24, 2026 | $0.92 | $0.28 | +229% | +11.1% | |
| 16 | Sarepta Therapeutics, Inc. | Healthcare | May 6, 2026 | $3.16— Maintained | $0.98 | +224% | -4.5% | |
We entered 2026 with clear priorities—stabilizing the business, restoring growth, maintaining financial strength, and advancing a pipeline that we believe can define Sarepta’s next era. | ||||||||
| 17 | CareDx, Inc | Healthcare | Apr 28, 2026 | $0.34↑ Raised | $0.11 | +209% | -4.8% | |
John W. Hanna, President and CEO Our team delivered another quarter of record growth, driven by continued momentum in our Precision Medicine Testing Services and Patient and Digital Solutions businesses. | ||||||||
| 18 | Acadia Healthcare Company, Inc. | Healthcare | Feb 25, 2026 | $0.07 | $0.03 | +133% | +29.8% | |
| 19 | Neogen Corporation | Healthcare | Apr 9, 2026 | $0.09 | $0.04 | +125% | -9.3% | |
| 20 | Supernus Pharmaceuticals, Inc. | Healthcare | May 5, 2026 | $0.59— Maintained | $0.28 | +111% | +5.9% | |
Our first quarter results reflect a strong start to the year, including a 56% year-over-year increase in combined revenues of our growth products. | ||||||||
| 21 | Xeris Biopharma Holdings, Inc. | Healthcare | Mar 2, 2026 | $0.06 | $0.03 | +100% | -2.9% | |
| 22 | Liquidia Corporation | Healthcare | Mar 5, 2026 | $0.15 | $0.08 | +87.5% | +4.8% | |
| 23 | Oscar Health, Inc. | Healthcare | May 6, 2026 | $2.07— Maintained | $1.11 | +86.5% | +16.3% | |
Oscar Health drove solid first-quarter performance with significant year-over-year improvements across our core metrics. | ||||||||
| 24 | Centene Corporation | Healthcare | Apr 28, 2026 | $3.37↑ Raised | $1.87 | +80.2% | +24.0% | |
Sarah M. London, Chief Executive Officer We continue to make tangible progress in our margin recovery efforts while strengthening the fundamental operations of each of our businesses. | ||||||||
| 25 | AnaptysBio, Inc. | Healthcare | Mar 3, 2026 | $1.58 | $0.89 | +77.5% | +10.3% | |
STAAR is off to a strong start in 2026, as reflected in our first quarter financial results. We have made meaningful advancements against our core objectives of Revenue Growth and Profit Expansion.
We started the year strong, focused on delivering for our clients with excellence and making advances in our strategic journey back to growth and margin expansion.
Our first-quarter performance demonstrates that Alignment continues to grow with discipline. We expanded our profitability by executing across sales, clinical operations and cost management, even as the Medicare Advantage environment continues to change.
We delivered a solid start to 2026, with first quarter revenue up 25% year-over-year and adjusted EBITDA of $6.2 million. Healthy demand for our biopreservation media and growth across our broader product portfolio reinforces our market leading position.
We delivered an exceptional quarter to begin the year, highlighted by strong revenue growth of 21%, net income growth of $13.5 million, and Adjusted EBITDA growth of 48%.
We entered 2026 with clear priorities—stabilizing the business, restoring growth, maintaining financial strength, and advancing a pipeline that we believe can define Sarepta’s next era.
Our team delivered another quarter of record growth, driven by continued momentum in our Precision Medicine Testing Services and Patient and Digital Solutions businesses.
Our first quarter results reflect a strong start to the year, including a 56% year-over-year increase in combined revenues of our growth products.
Oscar Health drove solid first-quarter performance with significant year-over-year improvements across our core metrics.
We continue to make tangible progress in our margin recovery efforts while strengthening the fundamental operations of each of our businesses.
Ranked by EPS miss % (worst first). Price reaction = day after report.
| # | Symbol | Company | Sector | Date | EPS Actual | EPS Est. | Surprise | Price Reaction |
|---|---|---|---|---|---|---|---|---|
| 1 | Madrigal Pharmaceuticals, Inc. | Healthcare | Feb 19, 2026 | -$2.57 | $0.04 | -6525% | -11.5% | |
| 2 | BioCryst Pharmaceuticals, Inc. | Healthcare | May 6, 2026 | -$2.98 | $0.06 | -5067% | -1.4% | |
| 3 | Hims & Hers Health, Inc. | Healthcare | May 11, 2026 | -$0.40↑ Raised | $0.04 | -1100% | -11.5% | |
2026 is a defining year for Hims & Hers. We're not just growing, we're pulling away from the field on our path to becoming the world's largest consumer health platform. | ||||||||
| 4 | Mirum Pharmaceuticals, Inc. | Healthcare | Feb 25, 2026 | -$0.11 | $0.02 | -650% | -14.2% | |
| 5 | AdaptHealth Corp. | Healthcare | May 5, 2026 | -$0.06↑ Raised | $0.01 | -580% | -12.5% | |
The opening months of 2026 have set the stage for what will be a defining year for AdaptHealth. We completed the largest de novo expansion in the history of the home medical equipment industry, delivering revenue well ahead of our first quarter guidance. | ||||||||
| 6 | InnovAge Holding Corp. | Healthcare | May 5, 2026 | -$0.22↑ Raised | $0.06 | -467% | -0.9% | |
We delivered a solid third quarter, reflecting continued improvement in operating execution and financial performance. | ||||||||
| 7 | Nanobiotix S.A. | Healthcare | Mar 31, 2026 | -$0.46 | $0.30 | -251% | +11.4% | |
| 8 | BioMarin Pharmaceutical Inc. | Healthcare | Feb 23, 2026 | -$0.24 | $0.17 | -242% | -2.3% | |
| 9 | STAAR Surgical Company | Healthcare | Mar 3, 2026 | -$0.20 | $0.18 | -211% | +0.9% | |
| 10 | Warby Parker Inc. | Healthcare | Feb 26, 2026 | -$0.04 | $0.05 | -180% | +14.9% | |
| 11 | Avadel Pharmaceuticals plc | Healthcare | Mar 2, 2026 | -$0.05 | $0.08 | -163% | — | |
| 12 | Cronos Group Inc. | Healthcare | Feb 26, 2026 | -$0.00 | $0.01 | -147% | -3.6% | |
| 13 | Telix Pharmaceuticals Limited | Healthcare | Feb 19, 2026 | -$0.01 | $0.03 | -135% | +20.0% | |
| 14 | Halozyme Therapeutics, Inc. | Healthcare | Feb 17, 2026 | -$0.24 | $2.15 | -111% | -7.8% | |
| 15 | Genmab A/S | Healthcare | Feb 17, 2026 | $0.05 | $0.46 | -89.1% | -2.9% | |
| 16 | Masimo Corporation | Healthcare | Feb 26, 2026 | $0.18 | $1.48 | -87.8% | +0.1% | |
| 17 | Amicus Therapeutics, Inc. | Healthcare | Feb 20, 2026 | $0.01 | $0.07 | -86.0% | +0.1% | |
| 18 | Privia Health Group, Inc. | Healthcare | May 7, 2026 | $0.02— Maintained | $0.08 | -75.0% | -3.9% | |
| 19 | BeOne Medicines Ltd. | Healthcare | Feb 26, 2026 | $0.58 | $1.60 | -63.8% | -10.0% | |
| 20 | Surgery Partners, Inc. | Healthcare | Mar 2, 2026 | $0.12 | $0.31 | -61.3% | -10.2% | |
| 21 | TG Therapeutics, Inc. | Healthcare | Feb 26, 2026 | $0.14 | $0.35 | -60.0% | +1.4% | |
| 22 | Harmony Biosciences Holdings, Inc. | Healthcare | Feb 24, 2026 | $0.38 | $0.84 | -54.8% | +4.9% | |
| 23 | TransMedics Group, Inc. | Healthcare | May 5, 2026 | $0.30— Maintained | $0.62 | -51.6% | -24.9% | |
We are pleased with our first quarter results and see 2026 as another critical period for TransMedics as we deliver on several critical growth catalysts for our business. | ||||||||
| 24 | ACADIA Pharmaceuticals Inc. | Healthcare | May 6, 2026 | $0.02— Maintained | $0.04 | -50.0% | +1.0% | |
Acadia delivered a solid first quarter of 2026 with total revenues of $268 million, driven by a strong start from DAYBUE, which generated sales of $101 million. | ||||||||
| 25 | Teleflex Incorporated | Healthcare | Feb 26, 2026 | $1.93 | $3.73 | -48.3% | +9.1% | |
2026 is a defining year for Hims & Hers. We're not just growing, we're pulling away from the field on our path to becoming the world's largest consumer health platform.
The opening months of 2026 have set the stage for what will be a defining year for AdaptHealth. We completed the largest de novo expansion in the history of the home medical equipment industry, delivering revenue well ahead of our first quarter guidance.
We delivered a solid third quarter, reflecting continued improvement in operating execution and financial performance.
We are pleased with our first quarter results and see 2026 as another critical period for TransMedics as we deliver on several critical growth catalysts for our business.
Acadia delivered a solid first quarter of 2026 with total revenues of $268 million, driven by a strong start from DAYBUE, which generated sales of $101 million.